Skip to content

Study · Animal study (in vivo) · rat · 2020

9 results

Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.

Gojkovic S, Krezic I, Vrdoljak B, Malekinusic D, Barisic I, Petrovic A, Horvat Pavlov K, Kolovrat M, Duzel A, Knezevic M, Kasnik Kovac K, Drmic D and 5 more

Show all authors

Batelja Vuletic L, Kokot A, Boban Blagaic A, Seiwerth S, Sikiric P

World journal of gastrointestinal pathophysiology1 Mar 2020Cited by 41 (Europe PMC)

PMID32226643 (opens in a new tab)PMCIDPMC7093306 (opens in a new tab)DOI10.4291/wjgp.v11.i1.1 (opens in a new tab)PepBankPUB-32226643
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 counteracted increased P wave amplitude, tachycardia and ST-elevation.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 counteracted heart rhythm changes seen on the ECG.

    Peptide
    BPC-157
    Outcome
    DecreaseElectrocardiogram disturbances (P wave amplitude, tachycardia, ST-elevation)
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 counteracted increased P wave amplitude, tachycardia and ST-elevation, i.e., right heart failure from acute thrombotic coronary occlusion.
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with suprahepatic inferior vena cava occlusion, the bypassing pathway via the azygos vein and a portocaval shunt occurred rapidly with BPC‑157.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 was followed by quick opening of bypass blood routes.

    Peptide
    BPC-157
    Outcome
    IncreaseBypassing pathway (inferior vena cava to azygos to superior vena cava, portocaval shunt)
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    The bypassing pathway of the inferior vena cava-azygos (hemiazygos) vein-superior vena cava and portocaval shunt occurred rapidly.
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 antagonized portal and caval hypertension even with severe caval hypertension.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 worked against high pressure in the portal and caval veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Even with severe caval ˃ portal hypertension, BPC 157 antagonized portal and caval hypertension
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 antagonized aortal hypotension.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 worked against low aortic blood pressure.

    Peptide
    BPC-157
    Outcome
    DecreaseAortal hypotension
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 antagonized portal and caval hypertension and aortal hypotension
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 reduced refractory ascites.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 reduced fluid build-up in the abdomen.

    Peptide
    BPC-157
    Outcome
    DecreaseRefractory ascites
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    and also reduced refractory ascites.
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 attenuated thrombosis of portal vein tributaries, inferior vena cava, and hepatic and coronary arteries.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 reduced blood clots in several veins and arteries.

    Peptide
    BPC-157
    Outcome
    DecreaseThrombosis of portal vein tributaries, inferior vena cava, hepatic and coronary arteries
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    Thrombosis of portal vein tributaries, inferior vena cava, and hepatic and coronary arteries was attenuated.
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 reduced lung and liver pathology and decreased intestinal hemorrhagic lesions.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 reduced damage in the lungs, liver and intestine.

    Peptide
    BPC-157
    Outcome
    DecreaseLung, liver and intestine pathology
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Organ injury · Whole body
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    there was reduced pathology of the lungs (severe capillary congestion) and liver (dilated central veins and terminal portal venules), decreased intestine hemorrhagic lesions (substantial capillary congestion, submucosal edema and architecture loss)
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats with suprahepatic inferior vena cava occlusion, liver nitric oxide and malondialdehyde levels stayed within normal healthy values during ligation with BPC‑157.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 kept two liver stress markers within normal values during the blockage.

    Peptide
    BPC-157
    Outcome
    No significant changeLiver nitric oxide and malondialdehyde levels during ligation
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Inflammation markers · Liver
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    During the period of ligation, nitric oxide- and malondialdehyde-levels in the liver remained within normal healthy values
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with suprahepatic inferior vena cava occlusion, BPC‑157 markedly reduced increases in serum enzymes.

    In plain wordsIn rats with a blocked liver vein, BPC‑157 markedly reduced rises in blood liver enzymes.

    Peptide
    BPC-157
    Outcome
    DecreaseSerum enzyme increases
    Study

    ratn: not reported in source

    Suprahepatic inferior vena cava ligation (Budd-Chiari syndrome model)
    Comparator
    Saline control
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 µg/kg, 10 ng · abdominal bath or intragastric · single administrationAs given in this study (rat).

    Source sentences

    Summary
    and increases in serum enzymes were markedly reduced.
    2 context sentences
    Summary · context
    Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min, 15 min, 24 h, or 48 h post-ligation.
    Summary · context
    Medication consisted of 10 µg/kg BPC 157, 10 ng BPC 157 or 5 mL/kg saline, administered once as an abdominal bath or intragastric application.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.